Nirsevimab: a change of paradigm in the prophylaxis of Respiratory Syncytial Virus disease among infants
Keywords:
.Abstract
.
References
1. Garattini L, Clavenna A. RSV prevention options for infants and older adults: A specific expanding competitive arena. Health Policy. 2024 Oct 20;150:105187. doi: 10.1016/j.healthpol.2024.105187. Epub ahead of print. PMID: 39442242.
2. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017 Sep 2; 390(10098):946-58. PMID: 28689664; PMCID: PMC5592248.
3. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5;360(6):588-98. doi: 10.1056/ NEJMoa0804877. PMID: 19196675; PMCID: PMC4829966.
4. Geoghegan S, Erviti A, Caballero MT, Vallone F, Zanone SM, Losada JV, et al. Mortality due to Respiratory Syncytial Virus. Burden and Risk Factors. Am J Respir Crit Care Med. 2017 Jan 1;195(1):96-103. doi:10.1164/rccm.201603-0658OC. PMID: 27331632.
5. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013 Aug;132(2):e341-e348. doi: 10.1542/peds.2013-0303. Epub 2013 Jul 22. PMID: 23878043.
6. Meissner HC. Viral Bronchiolitis in Children. New Eng J Med. 2016 Jan 7;374(1):62-72. https://doi. org/10.1056/NEJMra1413456. PMID: 26735994.
7. Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, et al. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatr Pulmonol. 2017 Apr;52(4):556-569. doi:10.1002/ ppul.23570. Epub 2016 Oct 14. PMID: 27740723; PMCID: PMC5396299.
8. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/ S0140-6736(22)00478-0. Epub 2022 May 19. PMID: 35598608; PMCID: PMC7613574.
9. Thomas E, Mattila JM, Lehtinen P, Vuorinen T, Waris M, Heikkinen T. Burden of Respiratory Syncytial Virus Infection During the First Year of Life. J Infect Dis. 2021 Mar 3;223(5):811-817. doi: 10.1093/infdis/ jiaa754. PMID: 33350450.
10. Scarpaci M, Bracaloni S, Esposito E, De Angelis L, Baglivo F, Casini B, et al. RSV Disease Burden in Primary Care in Italy: A Multi-Region Pediatric Study, Winter Season 2022-2023. Influenza Other Respir Viruses. 2024 Apr;18(4):e13282. doi: 10.1111/irv.13282. PMID: 38622776; PMCID: PMC11018906.
11. Vittucci AC, Antilici L, Russo C, Musolino AMC, Cristaldi S, Cutrera R, et al. Respiratory syncytial virus: can we still believe that after pandemic bronchiolitis is not a critical issue for public health?. Eur J Pediatr. 2023 Dec;182(12):5303-5313. doi: 10.1007/s00431-023-05201-y. Epub 2023 Sep 20. PMID: 37728752; PMCID: PMC10746572.
12. Bozzola E, Ciarlitto C, Guolo S, Brusco C, Cerone G, Antilici L, et al. Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost. Front Pediatr. 2021 Jan 18;8:594898. doi: 10.3389/ fped.2020.594898. PMID: 33537260; PMCID: PMC7848214.
13. Antilici L, Vittucci AC, Cristaldi S, Musolino AMC, Pisani M, Rotondi Aufiero L, et al. High-flow na sal cannulas versus standard oxygen therapy for moderate bronchiolitis: a quasi-experimental analysis. Pediatr Pulmonol. 2025 Jan; Epub 2024 Oct 25. doi: 10.1002/ppul.27358. PMID: 39451018; PMCID: PMC11740650.
14. Villani A, Vittucci AC, Antilici L, Pisani M, Scutari R, Di Maio VC, et al. Prevention of RSV Bronchiolitis: An Ethical Issue. Pediatr Infect Dis J. 2024 Aug;43(8):e296-e297. doi: 10.1097/INF.0000000000004354. Epub 2024 Apr 9. PMID: 38621157.
15. Sumsuzzman DM, Wang Z, Langley JM, Moghadas SM. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2025 Jun;9(6):393-403. doi: 10.1016/S2352-4642(25)00093-8. Epub 2025 May 1. PMID: 40319903.
16. Hak SF, Sankatsing VDV, Wildenbeest JG, Venekamp RP, Casini B, Rizzo C, et al; RSV ComNet Network.
Nirsevimab in the prophylaxis of Respiratory Syncytial Virus disease among infants 687
Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021-23). Lancet Respir Med. 2025 Feb;13(2):153-165. doi: 10.1016/S2213-2600(24)00367-9. Epub 2025 Jan 9. PMID: 39799949.
17. Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024 Aug;24(8):817-828. doi:10.1016/S1473-3099(24)00215-9. Epub 2024 Apr 30. PMID: 38701823.
18. Perramon-Malavez A, de Rioja VL, Coma E, Hermosilla E, Fina F, Martínez-Marcos M, et al. Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season. Eur J Pediatr. 2024 Dec;183(12):5181-5189. doi: 10.1007/s00431-02405779-x. Epub 2024 Sep 28. PMID: 39340677; PMCID: PMC11527896.
19. Jimeno Ruiz S, Peláez A, Labourt A, Acuña FM, Linares L, Llana Martín I, et al. Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines (Basel). 2024 Oct 11;12(10):1160. doi: 10.3390/vaccines12101160. PMID: 39460326; PMCID: PMC11510999.
20. Paireau J, Durand C, Raimbault S, Cazaubon J, Mortamet G, Viriot D, et al. Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024. Influenza Other Respir Viruses. 2024 Jun;18(6):e13311. doi:10.1111/irv.13311. PMID: 38840301; PMCID: PMC11154801.
21. Orsi A, Scarpaleggia M, Baldo V, Barbone F, Chironna M, Giuffrida S, et al. First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants. J Prev Med Hyg. 2024 Aug 31;65(2):E172-E187. doi:10.15167/2421-4248/jpmh2024.65.2.3329. PMID: 39430977; PMCID: PMC11487721.
22. Xu H, Aparicio C, Wats A, Araujo BL, Pitzer VE, Warren JL, et al. Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study (Preprint]. medRxiv. 2024 Sep 12:2024.09.12.24313545. doi: 10.1101/2024.09.12.24313545. PMID: 39314944; PMCID: PMC11419242.
23. Consolati A, Farinelli M, Serravalle P, Rollandin C, Apprato L, Esposito S, et al. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023-2024 Epidemic Season. Vaccines (Basel). 2024 May 17;12(5):549. doi:10.3390/vaccines12050549. PMID: 38793800; PMCID: PMC11125727.
24. Getaneh AM, Li X, Mao Z, Johannesen CK, Barbieri E, van Summeren J, et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries. Vaccine. 2023 Feb 24;41(9):1623-1631. doi:10.1016/j.vaccine.2023.01.058. Epub 2023 Feb 1. PMID: 36737318.
25. Silenzi A, Siddu A, D’Amelio AC, Cataldi S, Fasano C, Maraglino F, et al. The new Italian National Immunization Technical Advisory Group (NITAG) and its commitment to endorse a new efficient National Immunization Plan in COVID-19 times. Ann Ist Super Sanita. 2023 Jan-Mar;59(1):26-30. doi: 10.4415/ ANN_23_01_04. PMID: 36974701.
26. World Health Organization. WHO position paper on immunization to protect infants against respiratory syncytial virus disease, May 2025. Wkly Epidemiol Rec. 2025 May 30;100(22):193-218. Available from: https://iris.who.int/bitstream/handle/10665/381539/WER10022-eng-fre.pdf [Last accessed: 2025 Jun 9].
27. State-Regions Conference (Italy). 2024, Oct 17. Available from: https://www.statoregioni.it/media/ lhnb3llv/p-fs-csr-atto-rep-n-188-17ott2024.pdf [Last accessed: 2025 Jun 9].
28. Signorelli C, Oleari F, Greco D, Ruocco G, Guerra R, Rezza G, et al. The Italian National Vaccine Prevention Plans, 1999/2020-2023/2025: challenges and obstacles to vaccine coverage goals. Commentary. Ann Ist Super Sanita. 2024 Oct-Dec;60(4):247-251. doi: 10.4415/ANN_24_04_02. PMID: 39699977.
29. MilanoToday. 2025, Jan 30. Così la Lombardia sta ‘vincendo’ contro il virus sinciziale (la bronchiolite). Available from: https://www.milanotoday.it/attualita/ricoveri-bronchiolite-virus-sinciziale.html [Last accessed: 2025 Jun 9].
Letters
30. TorinoCronaca. 2025, Jan 6. Influenza per 500 mila. Nei pronto soccorso 200 accessi al giorno. Available from: https://torinocronaca.it/news/torino/438189/influenza-per-500mila-nei-pronto-soccorso-200accessi-al-giorno.html [Last accessed: 2025 Jun 9].
31. IVG. 2025, Mar 18. Bronchiolite in Liguria: 90% dei neonati vaccinato; casi diminuiti dell’88% in un anno. Available from: https://www.ivg.it/2025/03/bronchiolite-in-liguria-90-dei-neonati-vaccinatocasi-diminuiti-dell88-in-un-anno/ [Last accessed: 2025 Jun 9].
32. ANSA. 2025, Mar 18. Neonatologi Calabria, ok campagna vaccini contro virus sinciziale. Available from: https://www.ansa.it/calabria/notizie/2025/03/18/neonatologi-calabriaok-campagna-vaccinicontro-virus-sinciziale_0944c6ba-4c9c-490c-86fb-e5ae61d557ec.html [Last accessed: 2025 Jun
9].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Giovanni Rezza, Danilo Cereda, Caterina Rizzo, Rita Cuciniello, Anna Carole D'Amelio, Alberto Villani, Carlo Signorelli (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.